



Clinical Lab Intelligence

EDITION 010 | SEPTEMBER 10, 2026

Faster results, harder questions

The strongest new evidence centers on point-of-care workflows: speed matters, but specimen effects, pathway design, clinical outcomes, and error definitions decide whether faster testing is actually better.

READING KEY

Finding = what the source established. Why it matters = practice, education, or leadership relevance. Limits = what should not be overclaimed.

COVERAGE CHECK

The high-value interval was limited and concentrated. No DOI, canonical source, or substantially identical story from Editions 001-009 is repeated. Source cutoff: September 9, 2026.

Core developments

01 Point-of-care testing made decisions faster, but outcomes did not automatically follow

Pecoraro et al. | Clinical Chemistry and Laboratory Medicine | September 9, 2026 | Systematic review; full text may require access | [SOURCE](#)

Finding. Across 55 studies involving about 142,000 emergency-department patients, point-of-care testing shortened time to a treatment decision by 73-96 minutes and reduced emergency-department length of stay by a pooled 29.24 minutes. Major clinical outcomes did not differ significantly from central-laboratory testing.

Why it matters. Speed is an intermediate outcome, not proof of benefit. Laboratory leaders should pair analytical validation and connectivity with pathway redesign, defined action thresholds, staffing, and measures of disposition, treatment, safety, and equity.

Limits / cautions. The included tests, settings, and study designs were heterogeneous. The review found no significant major-outcome difference, so it does not establish that every point-of-care deployment is clinically equivalent or cost-effective.

02 Pediatric capillary CBC performance was analyte-dependent

Lai et al. | European Journal of Pediatrics | September 9, 2026 | Evaluation study; full text may require access | [SOURCE](#)

Finding. In 195 unselected pediatric emergency patients, capillary and venous point-of-care testing met desirable biological-variation specifications for MCHC, lymphocytes, and CRP. WBC and granulocytes met them only in venous samples, while RBC indices and platelets showed significant bias.

Why it matters. A device cannot be accepted or rejected as one unit. Verification, reporting limits, and clinician education should be analyte- and specimen-specific, with special attention to capillary collection and platelet or red-cell decisions.

Limits / cautions. Single-center, six-week evaluation of one system; dispersion may reflect capillary preanalytics as well as instrument performance. The authors declared no competing interests.

03 AI read MALDI-TOF spectra for Aspergillus susceptibility - and failed the clinical test

Lee et al. | Annals of Laboratory Medicine | September 8, 2026 | Peer-reviewed proof of concept; open access | [SOURCE](#)

Finding. Models trained on spectra from 240 Aspergillus isolates looked strong at the spectrum level, but isolate-level validation across seven species-drug combinations produced mean categorical agreement of 56.0%, with very major and major error rates of 53.3% and 45.2%.

Why it matters. This is a useful warning against substituting internal discrimination metrics for the error measures that matter at the bench. AI susceptibility tools require species-drug validation, independent external data, resistant-isolate representation, and explicit comparison with reference AST.

Limits / cautions. The validation set contained 70 isolates across three species and four drugs. Performance varied widely, and two authors were affiliated with the MALDI-TOF company; the study itself concludes that clinical adoption is premature.

04 Laboratory stewardship needs patient outcomes, not only fewer tests

Park and Don-Wauchope | Annals of Laboratory Medicine | September 7, 2026 | Peer-reviewed review; open access | [SOURCE](#)

Finding. Using the IFCC outcome framework, the review mapped stewardship evidence for ESR/CRP co-ordering, troponin with legacy markers, and vitamin D testing. Test-volume and cost reductions were well supported, but direct evidence for mortality, diagnostic trajectories, patient-centered outcomes, and safety remained limited.

Why it matters. A mature stewardship dashboard should distinguish utilization, operations, economics, patient management, safety, patient experience, clinical outcomes, and policy effects. That gives educators and leaders a better endpoint hierarchy than cost savings alone.

Limits / cautions. This is a review, not a new intervention trial. Much of the underlying evidence came from large academic centers, and prospective patient-level outcome data were sparse.

05 Analyzer-specific yield scaling improved pathogen-reduced platelet collection

Amato et al. | Annals of Laboratory Medicine | September 3, 2026 | Peer-reviewed original study; open access | [SOURCE](#)

Finding. In 4,383 apheresis procedures from 1,573 donors, adapting the Trima Accel yield-scaling factor to Sysmex XN1000 blood-bank-mode counts reduced target-yield deviation. The 1.05 setting also shortened donation time by about 8.1 minutes for large-volume and 9.9 minutes for dual-storage collections versus the earlier setup.

Why it matters. Changing the counter used for product measurement can change the collection system itself. Blood centers need paired-method comparison, controlled parameter changes, product-quality review, donor-time monitoring, and lot- or software-change governance.

Limits / cautions. Observational comparison of sequential device configurations at one center; the optimum scaling factor is system-specific and should not be transferred without local controlled study.

06 RhIG guidance is moving toward genotype-specific decisions

Jo et al. | Annals of Laboratory Medicine | September 8, 2026 | Peer-reviewed opinion; open access | [SOURCE](#)

Finding. The opinion argues that molecularly defined Asian-type DEL should be managed as RhD-positive for RhIG prophylaxis, while emphasizing that dosing and management remain unresolved for RhD variants with epitope deficiency.

Why it matters. Serologic weak or apparently negative reactions are not a complete transfusion-medicine phenotype. Laboratories need an RHD-genotyping referral pathway, unambiguous interpretive language, and alignment among blood bank, obstetric, and transfusion policies.

Limits / cautions. This is an expert opinion rather than a new outcomes study. Its genotype-specific proposals require reconciliation with national guidance, local policy, reagent behavior, ancestry-independent testing criteria, and specialist review.

07 ADLM released the 2026 meeting recordings as a targeted learning library

Association for Diagnostics & Laboratory Medicine | Available September 9, 2026 | Official educational resource | [SOURCE](#)

Finding. The recording library spans laboratory AI, digital microbiology, downtime and cyberattack recovery, proficiency testing, AST, accreditation, pediatric reference intervals, leadership, space medicine, data analytics, and other bench-to-boardroom topics. Access continues through July 31, 2027.

Why it matters. For MLS educators and laboratory leaders, the catalog can support a focused journal-club or competency-development sequence: select one operational problem, pair the recording with a primary source or standard, and document the resulting local question.

Limits / cautions. Recordings generally require purchase or included access, are not eligible for continuing-education credit, and are conference education rather than independently peer-reviewed evidence.

Unexpected Connections & Leads

Established evidence is separated from the proposed collaboration or research lead.

CRISPR plus microfluidics moved MRSA detection directly into whole blood

Huang et al. | ACS Sensors | September 8, 2026 | Peer-reviewed engineering and clinical evaluation | [SOURCE](#)

Established. A dual nucA/mecA RPA-CRISPR system combined vancomycin-coated magnetic particles, a herringbone chip, and a wireless analyzer. In 350 suspected-bacteremia patients it found all 20 culture-positive *Staphylococcus aureus* cases, including eight MRSA, in about two hours.

Collaboration lead. Microbiology, antimicrobial stewardship, emergency medicine, microfluidics, and device-regulatory teams could design a prospective pathway study that preserves culture and full AST while measuring time to active therapy and de-escalation.

Next question. Can the system maintain performance across low organism burdens, mecA-positive coagulase-negative staphylococci, polymicrobial blood, diverse resistance mechanisms, and routine operators?

Boundary. Only 20 *S. aureus*-positive and eight MRSA-positive cases were observed, so apparently perfect agreement has wide uncertainty; the assay does not replace culture or phenotypic susceptibility testing.

A thread-based sensor used the patient sample as part of the reagent system

Nohgi et al. | Lab on a Chip | September 8, 2026 | Peer-reviewed proof of concept | [SOURCE](#)

Established. A thread network separated plasma from whole blood by calcium-induced cell aggregation and used endogenous uric acid as the electrochemical mediator. With CRP as the model target, the integrated device reported a 0.106 mg/dL detection limit and near-100% recovery in three spike levels.

Collaboration lead. Clinical chemists, materials scientists, engineers, and POCT specialists could jointly define interference panels, calibration traceability, lot stability, whole-blood comparability, and human-factors requirements for reagent-light testing.

Next question. Does endogenous-mediator variation remain controlled in real patients with renal disease, hyperuricemia, drugs, anemia, inflammation, and changing hematocrit?

Boundary. Evidence was primarily analytical, with spiked material and a preliminary porcine inflammation model; there was no clinical human validation or patient-outcome study.

Feed-baited water bins sampled healthy wild birds without catching them

Rondi et al. | One Health | version of record August 16, 2026; newly indexed September 2026 | Peer-reviewed; open access | [SOURCE](#)

Established. Researchers tested 222 water samples after wild-bird visits along Germany's Baltic coast; 13 were influenza-A-positive, including highly pathogenic H5 and low-pathogenic H3N8 and H11N9. All four samples cultured for ESBL-producing *E. coli* were positive.

Collaboration lead. Veterinary, environmental, public-health, and clinical molecular laboratories could evaluate shared concentration controls, sequencing triggers, metadata, and reporting thresholds for noninvasive sentinel surveillance.

Next question. How do detection probability, subtype recovery, contamination, and cost compare with pooled swabs, passive carcass surveillance, and wastewater sampling across seasons?

Boundary. The field study ran in 2022-2023, only four samples underwent ESBL culture, and the method estimates environmental detection rather than prevalence or transmission in individual birds.

References

Every source cited in this issue is listed below with a full clickable direct link.

1. Pecoraro V, Banfi G, Trenti T, Fasano T. Impact of point of care testing in time to treatment decision-making in emergency departments: a systematic review. *Clinical Chemistry and Laboratory Medicine*. Published September 9, 2026. doi:10.1515/ccim-2026-0604. <https://doi.org/10.1515/ccim-2026-0604>
2. Lai G, Torchia A, Aiello G, et al. Evaluation of point-of-care complete blood count and C-reactive protein testing for routine use in a pediatric emergency department. *European Journal of Pediatrics*. Published September 9, 2026;185(10):730. doi:10.1007/s00431-026-07380-w. <https://doi.org/10.1007/s00431-026-07380-w>
3. Lee H, Seo D, Lee HJ, et al. Rapid Antifungal Susceptibility Classification of *Aspergillus* Species Using AI-Assisted Analysis of Routine MALDI-TOF MS Spectra: A Proof-of-Concept Study. *Annals of Laboratory Medicine*. Published September 8, 2026. doi:10.3343/alm.2026.0069. <https://doi.org/10.3343/alm.2026.0069>
4. Park K, Don-Wauchope AC. Laboratory Stewardship: Improving Quality of Care by Linking Clinical Outcomes to Appropriate Test Utilization in Clinical Chemistry Laboratories. *Annals of Laboratory Medicine*. Published September 7, 2026. doi:10.3343/alm.2026.0193. <https://doi.org/10.3343/alm.2026.0193>
5. Amato M, Siller A, Seekircher L, et al. Adaptation of the Yield-Scaling Factor to Reduce Target Yield Deviation and Donation Time in Pathogen-Reduced Apheresis Platelet Collections Using the Sysmex XN1000 Blood Bank Mode. *Annals of Laboratory Medicine*. Published September 3, 2026. doi:10.3343/alm.2026.0075. <https://doi.org/10.3343/alm.2026.0075>
6. Jo J, Sung ES, Nam M, Cho D. Refining RhIG Prophylaxis Guidelines: Asian-type DEL as RHD-Positive and Unresolved Dosing Challenges in RHD Epitope-Deficient Variants. *Annals of Laboratory Medicine*. Published September 8, 2026. doi:10.3343/alm.2026.0264. <https://doi.org/10.3343/alm.2026.0264>
7. Association for Diagnostics & Laboratory Medicine. ADLM 2026 Session Recordings List. Recordings available September 9, 2026 through July 31, 2027. Official meeting resource; accessed September 9, 2026. <https://meeting.mvadm.org/about/session-recordings/2026-session-recordings-list>
8. Huang H-Q, Zhang J-H, Hu X-F, et al. CRISPR-Based Diagnostic Assay for Point-of-Care Detection of Methicillin-Resistant *Staphylococcus aureus* in Patients with Bloodstream Infections. *ACS Sensors*. Published September 8, 2026. doi:10.1021/acssensors.6c01650. <https://doi.org/10.1021/acssensors.6c01650>
9. Nohgi T, Somrak S, Shang J, et al. A thread-based microfluidic electrochemical platform for whole-blood protein sensing using endogenous uric acid as a redox mediator. *Lab on a Chip*. Published September 8, 2026. doi:10.1039/d6lc00533k. <https://doi.org/10.1039/d6lc00533k>
10. Rondi FI, Neumann-Heise J, Harder T, et al. Water-Wheat-Wait: Monitoring wild mallards (*Anas platyrhynchos*) for avian influenza and ESBL-*E. coli* using feed-baited water bins, Germany, 2022 to 2023. *One Health*. 2026;23:101548. Version of record August 16, 2026. doi:10.1016/j.onehlt.2026.101548. <https://doi.org/10.1016/j.onehlt.2026.101548>

Source and link verification. Every hyperlink was checked as an HTTPS DOI resolver or an official professional, journal, or publisher page. URL shorteners, unknown file hosts, reposts, search-result links, unverified downloads, and social-media claims were excluded. This materially reduces risk, although no external site can be guaranteed permanently risk-free. Access labels may change. Findings are educational intelligence, not patient-specific medical advice.